Tempest Announces First Patient Dosed in Randomized Study Evaluating TPST-1120 in First-Line Regimen for Hepatocellular Carcinoma in Clinical Collaboration with Roche
September 20, 2021 08:00 ET
|
Tempest Therapeutics
SOUTH SAN FRANCISCO, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that...
Tempest Enters into Exclusive License Agreement with the University of California for Novel Cancer Target
September 13, 2021 08:00 ET
|
Tempest Therapeutics
• Russell Vance, PhD joins Tempest Advisory Board SOUTH SAN FRANCISCO, Calif., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company...
Tempest to Present at Upcoming Investor Conferences
September 09, 2021 16:01 ET
|
Tempest Therapeutics
SOUTH SAN FRANCISCO, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that...
Tempest Reports Second Quarter 2021 Financial Results and Provides Corporate Highlights
August 12, 2021 16:01 ET
|
Tempest Therapeutics
Closed merger transaction resulting in public listing (TPST)Closed $30M PIPE, extending runway into Q1’23Advancing TPST-1495 and TPST-1120 into targeted patient populationsAdvanced TREX-1...
Tempest Announces Appointment of Ronit Simantov, M.D. to its Board of Directors
August 09, 2021 08:00 ET
|
Tempest Therapeutics
SOUTH SAN FRANCISCO, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage oncology company developing potentially first-in-class...
Tempest to Participate in William Blair 2021 Biotech Focus Conference
July 09, 2021 08:00 ET
|
Tempest Therapeutics
SOUTH SAN FRANCISCO, Calif., July 09, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that...
Tempest Announces Appointment of Christine Pellizzari to its Board of Directors
July 01, 2021 16:00 ET
|
Tempest Therapeutics
SOUTH SAN FRANCISCO, July 01, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage oncology company developing potentially first-in-class therapeutics...
Tempest Closes Merger with Millendo and Completes PIPE Financing
June 28, 2021 07:50 ET
|
Tempest Therapeutics
SOUTH SAN FRANCISCO, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage oncology company developing potentially first-in-class...
Tempest and Millendo Announce Stockholder Approval of Merger
June 22, 2021 16:00 ET
|
Tempest Therapeutics
SOUTH SAN FRANCISCO, Calif. and ANN ARBOR, Mich., June 22, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (“Tempest”), a clinical-stage oncology company developing potentially first-in-class...
Tempest Therapeutics to Present at the Jefferies Healthcare Conference
May 27, 2021 08:00 ET
|
Tempest Therapeutics
SOUTH SAN FRANCISCO, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc., a clinical-stage oncology company developing first-in-class therapeutics that combine both precision and...